

**IN RE: GLUCAGON-LIKE
PEPTIDE-1 RECEPTOR AGONISTS
(GLP-1 RAS) PRODUCTS
LIABILITY LITIGATION**

• •
• •
• •
• •
• •
• •
• •
• •
• •

MDL No. 3094
24-md-3094

• • • • •

ALL ACTIONS/ALL CASES

AND NOW, this 23rd day of February, 2026, upon consideration of the parties' joint request to extend the case management deadlines as to Cross Cutting Issues 2 and 3, it is **ORDERED** that for good cause shown, the request is **GRANTED**, and the deadlines for Cross Cutting Issues 2 and 3 are **AMENDED** as follows:

April 24, 2026	Deadline for all parties to complete expert depositions
May 12, 2026	Deadline for the submission of motions to exclude expert opinions under Rule 702 and initial briefs
May 14, 2026	Deadline for the submission of summary judgment motions and initial briefs
June 17, 2026	Deadline for the submission of briefs in opposition to Rule 702 motions
June 30, 2026	Deadline for the submission of briefs in opposition to summary judgment motions
July 15, 2026	Deadline for the submission of reply briefs in support of Rule 702 motions

August 7, 2026	Deadline for the submission of reply briefs in support of summary judgment motions
----------------	--

IT IS SO ORDERED.

/s/Karen Spencer Marston

KAREN SPENCER MARSTON, J.